Skip to content

Abstract B105: Multisite single-cell immune profiling of premetastatic pancreatic ductal adenocarcinoma in a prospective clinical trial

Sep 2026 · Cancer Research · Vol 86, pp. B105-B105 · 0 citations

TL;DR

A large dataset provides a unique opportunity to expand a previously established multisite immune profiling platform to characterize immune microenvironment cell type composition across tissues, identify tissue-specific differences in patients with early versus late recurrence, and evaluate the effects of systemic chemotherapy on the tumor and surrounding tissue immune microenvironment.

Abstract

Although pancreatic ductal adenocarcinoma (PDAC) has long been considered immunologically "cold," recent studies have revealed complexity in how neoantigen quality, T cell composition, and spatial immune organization influence patient outcomes and responsiveness to emerging immune-based therapies. However, these investigations have largely focused on the primary tumor in isolation, and it remains poorly understood how this integrates with systemic immune responses across the patient and at metastatic sites. We previously developed a multisite immune profiling platform integrating the primary tumor, peripheral blood, and the pre-metastatic liver—the most common site of distant recurrence in PDAC. Here, we applied this platform to a larger panel of patients and healthy donor controls as part of the correlative studies for a prospective clinical trial to more comprehensively understand the coordinated immune landscape of PDAC across multiple tissue compartments. Twenty patients with resectable/borderline resectable PDAC were prospectively enrolled on a clinical trial (NCT05634720) evaluating preoperative hepatic artery infusion chemotherapy. Matched CD45+ immune cells were isolated from the primary tumor, pre-metastatic liver, and peripheral blood, while matched non-immune cells were also collected from the primary tumor. Paired single-cell RNA sequencing and T-cell receptor (TCR) sequencing were performed, with healthy donor peripheral blood samples serving as controls. The study prospectively enrolled two prespecified cohorts: patients undergoing upfront surgery and those receiving three months of neoadjuvant FOLFIRINOX, allowing planned comparisons of systemic chemotherapy-induced changes in immune composition, transcriptional state, and T-cell clonal architecture across all three tissue compartments. In total, 1,898,523 immune cells and 98,635 non-immune cells were sequenced from twenty-six patients. Ongoing analysis is focused on defining immune cell composition and transcriptional states across tissue compartments, characterizing T-cell clonal relationships and trafficking between sites, and determining associations between multisite immune features and clinical outcomes, including recurrence and survival. This large dataset provides us with a unique opportunity to expand a previously established multisite immune profiling platform to characterize immune microenvironment cell type composition across tissues, identify tissue-specific differences in patients with early versus late recurrence, and evaluate the effects of systemic chemotherapy on the tumor and surrounding tissue immune microenvironment. Neha Majety, Ethan S. Agritelley, Elishama N. Kanu, Ashley A. Fletcher, David Severson, Babu Sannareddy, Julia Button, Jiayin Bao, Nicholas Klemen, Peter J. Allen, Daniel Nussbaum, Erika Crosby. Multisite single-cell immune profiling of premetastatic pancreatic ductal adenocarcinoma in a prospective clinical trial [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr B105.

View source

Similar papers

Sep 2026

Abstract B096: Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer

It is suggested that productive immunotherapy responses in PDAC require not only tumor-reactive T cells, but also a stromal-vascular niche capable of supporting their recruitment, recirculation and persistence.

Sarah Kang, M. Parikh, Leontios Pappas et al. · 0 citations
Review Sep 2026

Abstract B033: Integrating spatial biology and peripheral blood biomarkers to map treatment resistance in pancreatic ductal adenocarcinoma

Despite recent advances in RAS-directed therapy, pancreatic ductal adenocarcinoma (PDAC) remains highly lethal. Surgical resection, chemotherapy, and radiotherapy continue to anchor treatment, but therapeutic resistance is pervasive, and most patients succumb to treatment-refractory residual disease. Advances in sing...

D. Olgun, Beatrice Awasthi, N. Lester et al. · 0 citations
Sep 2026

Abstract A040: Intratumor stem cell repertoire in pancreatic cancer

Metastatic pancreatic ductal adenocarcinoma (PDAC) is difficult to manage, has an overall survival of approximately nine months, and will soon be the second leading cause of death among cancers. The poor outcome of PDAC patients has been attributed, in part, to a pattern of intratumor heterogeneity reflected in the g...

Wa Xian, Frank Mckeon, J. Ajani et al. · 0 citations
Sep 2026

Abstract PR007: Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations

The findings define a spatially and molecularly resolved view of PDAC where epithelial states, microenvironments, and genomic alterations converge to shape disease progression, offering a basis for therapeutic targeting and stratification.

Noor Shakfa, Ferris Nowlan, Sibyl Drissler et al. · 0 citations
Open access Oct 2026

Tumor DNA methylation subtypes and expression levels of CFISH predict response and overall survival to immunochemotherapy.

BACKGROUND Predicting patient response to immunochemotherapy is vital but challenging and poorly studied in the (neo)adjuvant setting. We showed that tumor monocyte content (TMC) predicts overall survival of advanced esophageal cancer (OC) in response to immunochemotherapy. We report clinical outcomes of 35 operable OC...

Hannah Fuchs, Phil F. Xie, Sabrina A. James et al. · 0 citations
Review Open access Oct 2026

Biomarker-guided immunotherapy in osteosarcoma: from immune microenvironment profiling to patient stratification and combination strategies

Prospective studies should use standardized, spatially resolved, and longitudinal biomarker panels to enrich trials, distinguish prognostic from predictive effects, and adapt therapy when immune exclusion or antigen escape emerges, as well as define a practical framework for biomarker-guided immunotherapy.

Qing-Qing Li · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.